• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤微环境中的趋化因子：对肺癌和免疫治疗的影响

Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy.

作者信息

Jung Haebeen, Paust Silke

机构信息

The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.

出版信息

Front Immunol. 2024 Jul 16;15:1443366. doi: 10.3389/fimmu.2024.1443366. eCollection 2024.

DOI:10.3389/fimmu.2024.1443366
PMID:39114657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11304008/
Abstract

The tumor microenvironment (TME) is a complex interconnected network of immune cells, fibroblasts, blood vessels, and extracellular matrix surrounding the tumor. Because of its immunosuppressive nature, the TME can pose a challenge for cancer immunotherapies targeting solid tumors. Chemokines have emerged as a crucial element in enhancing the efficacy of cancer immunotherapy, playing a direct role in immune cell signaling within the TME and facilitating immune cell migration towards cancer cells. However, chemokine ligands and their receptors exhibit context-dependent diversity, necessitating evaluation of their tumor-promoting or inhibitory effects based on tumor type and immune cell characteristics. This review explores the role of chemokines in tumor immunity and metastasis in the context of the TME. We also discuss current chemokine-related advances in cancer immunotherapy research, with a particular focus on lung cancer, a common cancer with a low survival rate and limited immunotherapy options.

摘要

肿瘤微环境（TME）是围绕肿瘤的免疫细胞、成纤维细胞、血管和细胞外基质组成的复杂相互连接网络。由于其免疫抑制特性，TME可能对针对实体瘤的癌症免疫疗法构成挑战。趋化因子已成为增强癌症免疫疗法疗效的关键因素，在TME内的免疫细胞信号传导中发挥直接作用，并促进免疫细胞向癌细胞迁移。然而，趋化因子配体及其受体表现出依赖于背景的多样性，需要根据肿瘤类型和免疫细胞特征评估它们的促肿瘤或抑制作用。本综述探讨了趋化因子在TME背景下在肿瘤免疫和转移中的作用。我们还讨论了癌症免疫疗法研究中当前与趋化因子相关的进展，特别关注肺癌，这是一种生存率低且免疫疗法选择有限的常见癌症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/38226c2ffa7f/fimmu-15-1443366-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/3d07d43ef4ab/fimmu-15-1443366-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/21e451bb8128/fimmu-15-1443366-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/38226c2ffa7f/fimmu-15-1443366-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/3d07d43ef4ab/fimmu-15-1443366-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/21e451bb8128/fimmu-15-1443366-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8ab/11304008/38226c2ffa7f/fimmu-15-1443366-g003.jpg

相似文献

1
Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy.肿瘤微环境中的趋化因子：对肺癌和免疫治疗的影响
Front Immunol. 2024 Jul 16;15:1443366. doi: 10.3389/fimmu.2024.1443366. eCollection 2024.
2
Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants.增强肺部肿瘤免疫微环境中的免疫反应：策略和佐剂的全面综述。
Int Rev Immunol. 2024;43(5):280-308. doi: 10.1080/08830185.2024.2333275. Epub 2024 Mar 25.
3
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.mTOR 在肿瘤免疫微环境中的新作用：对趋化因子相关免疫细胞迁移的影响。
Theranostics. 2020 May 15;10(14):6231-6244. doi: 10.7150/thno.45219. eCollection 2020.
4
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.癌症免疫治疗中趋化因子导向的肿瘤微环境调节
Int J Mol Sci. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804.
5
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.癌症微环境中的趋化因子及其在癌症免疫治疗中的相关性。
Nat Rev Immunol. 2017 Sep;17(9):559-572. doi: 10.1038/nri.2017.49. Epub 2017 May 30.
6
Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.趋化因子/趋化因子受体在肿瘤发生中的作用研究进展：以胰腺癌为例。
Eur J Pharmacol. 2024 Mar 15;967:176357. doi: 10.1016/j.ejphar.2024.176357. Epub 2024 Feb 1.
7
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.肿瘤内调节性 T 细胞：标志物、亚群及其对抗肿瘤免疫的影响。
Immunology. 2019 Jul;157(3):232-247. doi: 10.1111/imm.13067. Epub 2019 Jun 3.
8
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.CCL7 招募 cDC1 以促进抗肿瘤免疫并促进非小细胞肺癌的检查点免疫治疗。
Nat Commun. 2020 Nov 30;11(1):6119. doi: 10.1038/s41467-020-19973-6.
9
Role of chemokine receptors in thyroid cancer and immunotherapy.趋化因子受体在甲状腺癌和免疫治疗中的作用。
Endocr Relat Cancer. 2019 Aug;26(8):R465-R478. doi: 10.1530/ERC-19-0163.
10
Shedding light on macrophage immunotherapy in lung cancer.揭示肺癌中巨噬细胞免疫疗法的奥秘。
J Cancer Res Clin Oncol. 2023 Aug;149(10):8143-8152. doi: 10.1007/s00432-023-04740-z. Epub 2023 Apr 13.

引用本文的文献

1
Correspondence on "METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation" by Tong .关于童等人的“METTL3通过m6A依赖的CXCL5/CCL5调控促进膀胱癌的免疫抑制微环境”的通信。
J Immunother Cancer. 2025 Jul 8;13(7):e012565. doi: 10.1136/jitc-2025-012565.
2
Integrative bioinformatics analysis of high-throughput sequencing and in vitro functional analysis leads to uncovering key hub genes in esophageal squamous cell carcinoma.高通量测序的整合生物信息学分析与体外功能分析有助于揭示食管鳞状细胞癌中的关键枢纽基因。
Hereditas. 2025 Mar 14;162(1):38. doi: 10.1186/s41065-025-00398-4.
3

本文引用的文献

1
Structural basis of dimerization of chemokine receptors CCR5 and CXCR4.趋化因子受体 CCR5 和 CXCR4 二聚化的结构基础。
Nat Commun. 2023 Oct 13;14(1):6439. doi: 10.1038/s41467-023-42082-z.
2
CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.CR5/CCL5 轴与不良预后相关，抑制该轴可减少口腔鳞状细胞癌的转移。
J Cancer Res Clin Oncol. 2023 Dec;149(19):17335-17346. doi: 10.1007/s00432-023-05443-1. Epub 2023 Oct 13.
3
MMP-9 and CCR7 as Possible Predictors of Lymph Node Metastasis in Laryngeal Squamous Cell Carcinoma.
HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment.
HIFU-CCL19/21轴增强肿瘤微环境中树突状细胞疫苗的疗效。
Pharmaceutics. 2025 Jan 6;17(1):65. doi: 10.3390/pharmaceutics17010065.
基质金属蛋白酶-9和趋化因子受体7作为喉鳞状细胞癌淋巴结转移的可能预测指标
Iran J Pathol. 2023 Spring;18(2):156-164. doi: 10.30699/ijp.2023.563014.2986. Epub 2023 Jun 20.
4
The global burden of lung cancer: current status and future trends.全球肺癌负担：现状与未来趋势。
Nat Rev Clin Oncol. 2023 Sep;20(9):624-639. doi: 10.1038/s41571-023-00798-3. Epub 2023 Jul 21.
5
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.免疫治疗持续时间与晚期非小细胞肺癌患者总生存期的相关性。
JAMA Oncol. 2023 Aug 1;9(8):1075-1082. doi: 10.1001/jamaoncol.2023.1891.
6
CCL19 dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.CCL19 树突状细胞增强了抗 PD-(L)1 免疫疗法在三阴性乳腺癌中的临床获益。
Med. 2023 Jun 9;4(6):373-393.e8. doi: 10.1016/j.medj.2023.04.008. Epub 2023 May 17.
7
Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy.C-X-C 基序趋化因子受体 4 导向的分子成像和治疗的观察者间协议率。
Clin Nucl Med. 2023 Jun 1;48(6):483-488. doi: 10.1097/RLU.0000000000004629. Epub 2023 Mar 22.
8
Combined targeting of CCL7 and Flt3L to promote the expansion and infiltration of cDC1s in tumors enhances T-cell activation and anti-PD-1 therapy effectiveness in NSCLC.联合靶向CCL7和Flt3L以促进肿瘤中cDC1的扩增和浸润，可增强非小细胞肺癌中T细胞的活化及抗PD-1治疗效果。
Cell Mol Immunol. 2023 Jul;20(7):850-853. doi: 10.1038/s41423-023-00991-5. Epub 2023 Mar 9.
9
Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B.通过基因修饰使 NK 细胞表达趋化因子受体 CCR4 和 CCR2B 实现高效重定向。
Int J Mol Sci. 2023 Feb 4;24(4):3129. doi: 10.3390/ijms24043129.
10
Lung cancer immunotherapy: progress, pitfalls, and promises.肺癌免疫疗法：进展、陷阱和前景。
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.